EV Surge Replacing Global Oil Flows Amid Crisis Today
A Middle East crisis sent oil prices higher and spotlighted a rapid shift to electric vehicles. New data show the wor...
Why Benchmarks Matter
Benchmarks provide objective yardsticks to assess results, set expectations, and keep portfolios aligned with objectives.
20,321 articles
U.S. Producers Could Get Billion-Dollar Boost From Oil
Oil prices stay elevated, lifting a near-term windfall for U.S. producers by roughly $63 billion. But a protracted Ir...
Musk Says Tesla, SpaceX Chip Project to Start in Texas
Elon Musk announced a Texas-based Terafab chip initiative, a joint venture between TESLA and SPACE X, to build advanc...
U.S. Stocks Look Cheap as Valuations Turn Favorable
Big-cap U.S. stocks are trading at more attractive levels after a year of resilience and rising macro uncertainty. An...
Israel Strikes Iran’s Nuclear Sites, Markets React
Israel launched airstrikes on Iran’s nuclear facilities, drawing Iran’s vow of retaliation and sending tremors throug...
Vanguard Energy No-Brainer Right: Is It Time to Buy?
With energy costs on the rise, investors ask if the Vanguard Energy ETF is a no-brainer right now. This guide breaks ...
Died Suicide Denver Airport: Financial Lessons for Families After Tragedy
A tragic incident at Denver Airport drew headlines, but the lasting impact is felt in the wallets and futures of thos...
Bitcoin Faces Treasury Yield Pressure as Japan Sells US Debt
Japan's quarterly sale of US Treasuries jolts bond markets, amplifying yield moves that could shape Bitcoin and other...
Target Corp After Latest Earnings: Is It a Buy Now?
Target Corp after latest earnings has investors weighing risk and reward. This guide breaks down what the numbers mea...
Boxx Mimics Treasury Yields, IRS Probes Tax Tactics
Alpha Architect’s BOXX aims to reproduce short-term Treasury returns without income distributions, but the IRS is exa...
Decades of History Tell Anything: Biotech Near $50 Set to Soar
A cash-generative biotech near $50 is drawing buyers amid a market shift toward defensible healthcare names. Here’s w...
Crispr Therapeutics Editas Medicine: Better Buy in 2026?
Two top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status